Clinical Trial Update: Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating octreotide to prevent diarrhea in patients receiving pelvic radiotherapy across multiple pelvic cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Prostate Cancer
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• Sandostatin (Octreotide acetate)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Cervical Cancer, Colorectal Cancer | Phase 3 | Status: COMPLETED